Table 6.
Incidence or Progression (95% CI) |
Regression (95% CI) |
Mortality (95% CI) |
||||||
Level 1 to Level 2 |
Level 2 to Level 3 |
Level 3 to Level 4 |
Level 4 to Level 5 |
Level 2 to Level 1 |
Level 3 to Level 2 |
Level 4 to Level 3 |
Any AMD to Death |
|
Baseline intensity, | ||||||||
relative to mortality | 0.88 | 1.54 | 4.73 | 2.49 | 0.44 | 0.10 | 0.20 | |
(0.70–1.41) | (1.07–2.21) | (1.89–11.83) | (0.80–7.70) | (0.29–0.68) | (0.01–1.70) | (0.02–2.20) | ||
Covariate HR | ||||||||
Age, per 5 years | 1.58 | 1.51 | 1.29 | 1.25 | 1.67 | |||
(1.50–1.67) | (1.39–1.64) | (1.14–1.46) | (0.99–1.57) | (1.62–1.71) | ||||
Sex, male | 0.90 | 0.63 | 0.85 | 1.25 | 1.55 | |||
(0.74–1.10) | (0.47–0.85) | (0.56–1.29) | (0.99–1.57) | (1.42–1.70) | ||||
CFH Y402H genotype | ||||||||
TT | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||
CT | 1.46 | 1.61 | 1.72 | 1.58 | 0.94 | |||
(1.17–1.82) | (1.18–2.20) | (1.07–2.76) | (0.63–3.99) | (0.86–1.03) | ||||
CC | 2.27 | 2.75 | 1.62 | 1.39 | 1.00 | |||
(1.71–3.01) | (1.81–4.18) | (0.92–2.83) | (0.45–4.32) | (0.87–1.14) | ||||
AMD severity | ||||||||
Level 1 | 1.00 | |||||||
Level 2 | 1.13 | |||||||
(0.93–1.36) | ||||||||
Level 3 | 0.68 | |||||||
(0.35–1.30) | ||||||||
Level 4 | 1.60 | |||||||
(0.94–2.75) | ||||||||
Level 5 | 1.23 | |||||||
(1.01–1.50) |
Level 1, no AMD; level 2, minimally severe early AMD; level 3, moderately severe early AMD; level 4, severe early AMD; level 5, late AMD. Estimates are mutually adjusted for all other covariates listed in the table. Bold text indicates results that were significant at the 5% level.